Cytoplasmic HuR expression has been implicated in the malignancy of several types of carcinomas, such as colon, ovary, breast, salivary, uterus, larynx and prostate cancers, and has been postulated to contribute towards the cancerous malignant phenotype (Erkinheimo et al, 2003; López de Silanes et al, 2003, 2005; Denkert et al, 2004; Heinonen et al, 2005; Cho et al, 2007a, 2007b; Niesporek et al, 2008). Here, ELAVL1 is linked to prostate carcinoma.